Physician profile
Laura E Kaplan
NPI 1508358409
$565.11
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.45 · 2020: $150 · 2021: $285 · 2022: $112.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.13 | 2021 | |
| Ucb, INC. | $112.13 | 2022 | |
| Galderma Laboratories, L.P. | $103.06 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $66.98 | 2020-2021 | |
| Lilly USA, LLC | $60.46 | 2019-2020 | |
| Genzyme Corporation | $43.71 | 2020 | |
| Vyne Pharmaceuticals INC. | $29.91 | 2021 | |
| Kyowa Kirin, INC. | $23.73 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.